The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a more substantial decrease in body mass and benefit metabolic function, particular